Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.

[1]  L. Notarangelo,et al.  SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. , 2018, Blood.

[2]  E. Holler,et al.  EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.

[3]  S. Kozlovskaya,et al.  A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  L. Notarangelo,et al.  Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. , 2017, Blood.

[5]  J. Tisdale,et al.  At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. , 2017, Blood.

[6]  C. Dvorak,et al.  Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. , 2017, Hematology/oncology clinics of North America.

[7]  A. Schulz,et al.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation , 2017, Bone Marrow Transplantation.

[8]  J. Puck,et al.  Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID , 2017, Bone Marrow Transplantation.

[9]  L. Notarangelo,et al.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects afte , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  C. Dvorak,et al.  Transplacental maternal engraftment and posttransplantation graft‐versus‐host disease in children with severe combined immunodeficiency , 2017, The Journal of allergy and clinical immunology.

[11]  Aashish N. Adhikari,et al.  Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. , 2016, The New England journal of medicine.

[12]  A. Egberts,et al.  Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. , 2016, The Lancet. Haematology.

[13]  B. Burkhardt,et al.  The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. , 2016, Blood.

[14]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[15]  T. Fleisher.  Transplantation Outcomes for Severe Combined Immunodeficiency 2000–2009 , 2015, Pediatrics.

[16]  D. French,et al.  Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation Into Routine Clinical Use , 2015, Therapeutic drug monitoring.

[17]  P. Thall,et al.  Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation , 2015, Bone Marrow Transplantation.

[18]  L. Notarangelo,et al.  Immune deficiencies, infection, and systemic immune disordersComparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency , 2014 .

[19]  L. Notarangelo,et al.  Transplantation outcomes for severe combined immunodeficiency, 2000-2009. , 2014, The New England journal of medicine.

[20]  L. Notarangelo,et al.  Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. , 2014, The Journal of allergy and clinical immunology.

[21]  U. Pannicke,et al.  SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. , 2014, Blood.

[22]  F. Alt,et al.  A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. , 2013, The Journal of allergy and clinical immunology.

[23]  S. Pai,et al.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  E. Haddad,et al.  B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? , 2013, The Journal of allergy and clinical immunology.

[25]  L. Baxter‐Lowe,et al.  Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34+ cells and a fixed CD3+ dose , 2013, Bone Marrow Transplantation.

[26]  J. Puck.  Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. , 2012, The Journal of allergy and clinical immunology.

[27]  A. Fischer,et al.  Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. , 2011, Blood.

[28]  Catherine J. Wu,et al.  In mixed hematopoietic chimerism, the donor red cells win , 2011, Haematologica.

[29]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  C. Dvorak,et al.  Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  L. Baxter‐Lowe,et al.  Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders , 2008, Bone Marrow Transplantation.

[32]  A. Fischer,et al.  Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. , 2007, Blood.

[33]  R. Setroikromo,et al.  Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice , 1998, Bone Marrow Transplantation.

[34]  W. Plunkett,et al.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine , 1996, Cancer Chemotherapy and Pharmacology.